封面
市場調查報告書
商品編碼
928001

胎牛血清的全球市場:成長,趨勢,預測(2020年~2025年)

Fetal Bovine Serum Market - Growth, Trends, and Forecast (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence | 英文 122 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球胎牛血清市場在預測期間內預計將以約9.1%的年複合成長率成長。胎牛血清,對開發藥劑中劃時代的研究很重要,在細胞為基礎的製藥研究有廣泛的用途。

本報告提供全球胎牛血清市場調查,市場概要,各產品、用途、終端用戶、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 研究用的胎牛血清的需求不斷提升
    • 生物醫藥品產業的擴大
    • 研究的投資和資金的增加
  • 阻礙市場要素
    • 高成本與產品病毒混入的可能性
    • 乳製品及肉品的需求的增加牛群的減少
  • 波特的五力分析

第5章 市場細分化

  • 各產品
    • 木炭加工
    • 層析法
    • 透析完畢FBS
    • 外吐小體消除完畢
    • 幹細胞
    • 其他
  • 各用途
    • 生物醫藥品
    • 細胞培養
    • 人和動物的疫苗生產
    • 其他
  • 各終端用戶
    • 研究機關
    • 生物科技、製藥公司
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Bovogen Biologicals Pty Ltd
    • GE Healthcare
    • HiMedia Laboratories
    • Merck KGaA
    • PAN-Biotech
    • R&D Systems, Inc
    • Rocky Mountain Biologicals
    • TCS Biosciences Ltd.
    • Thermo Fisher Scientific

第7章 市場機會及未來趨勢

簡介目錄
Product Code: 68212

The global fetal bovine serum market is estimated to grow with a CAGR of nearly 9.2% during the forecast period 2021-2026.

The COVID-19 pandemic is expected to have a positive impact on the fetal bovine serum market. Fetal bovine serum is used extensively in in-vitro cell-culture preparation and vaccine production. Fetal bovine serum is used as a supplement in the growth media for vaccines. Due to the high transmission rate and lack of treatment, many countries are suffering due to the impact of the pandemic, and they are continuing to bear a significant burden on both their economies and healthcare systems. Many countries were and are still under lockdown. They suspended the trades with other countries and implemented travel restrictions, leading to a decline in the market capitalizations of major companies across the world. However, the situation is improving gradually. The current COVID-19 outbreak is having a positive impact on the growth of the market as biopharmaceutical innovators are at the forefront of in vitro research and development for the search of vaccine and antiviral. The in vitro evaluation of vaccine and antivirals generally requires a culture media in which the targeted virus or bacteria is cultured and the response is identified. The rising focus of pharmaceutical industries on research and development is fueling the demand for culture media, further fueling demand for fetal bovine serum.

According to a research article titled 'Role of Viral Transport Media in Sustaining COVID-19 Testing' published in October 2020, Viral Transport Media is generally composed of Fetal Bovine Serum (FBS). A viral transport media is used for preserving and transporting samples. A viral transport media (VTM) is preferred over other types, as it is a non-toxic mixture of antimicrobials and buffered solutions that can preserve the COVID-19 virus while eliminating contaminant flora that might interfere with testing. Fetal Bovine Serum-based VTM has proven compatibility with a wide range of clinical tests from PCR to direct antigen testing to culture, allowing different tests to be run from the same sample. Thus, the fetal bovine serum market is expected to experience rapid growth.

Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. However, the FDA has put several requirements for the production process due to the risk of contamination. The increase in demand from users of traditional serum and the advancement in the research and academic initiatives by the private and government sectors are the major factors contributing toward the market growth. Fetal bovine serum is very important for novel research in drug development, and it finds diverse applications in cell-based biopharmaceutical research. Fetal bovine serum is an important feedstock in the pharmaceutical, biotechnology, and veterinary industries. Thus, the expansion of these industries is anticipated to fuel the global fetal bovine serum market growth.

Additionally, fetal bovine serum is also used as an additional media supplement for cell culture due to the high content of embryonic growth-promoting factors. The serum is considered one of the most effective growth promoters compared to the other animal-based serums available for most cell culture systems, indicative of an increase in the use of fetal bovine serum, which is expected to fuel the market growth.

Alternatively, scientific and ethical concerns are associated with the potential misuse of biotechnology research practices. There is also a lack in the number of skilled personnel due to which the fetal bovine serum market growth is restricted. In addition, the fetal bovine serum market is experiencing a major shift, primarily due to a significant rise in prices of fetal bovine serum over the recent years, which also acts as a key restraint.

Key Market Trends

The Stem Cell Segment is Expected to Witness a Good Growth Over the Forecast Period

Stem cells have a wide range of applications in research studies as well in the biopharmaceutical industry, owing to which the market value for stem cells is the highest, as compared to the markets for other product types. The efficacy of cellular reprogramming for induced pluripotent stem cells leads to the high demand for the product. Stem cells have advantages over other stem cell types due to the broad variety of their tissue sources. The broader range of application of the stem cell is likely to fuel the segmental growth, as it requires fetal bovine serum cell line for tissue culture. In addition, the advantages of FBS in serum cell culture, such as its ability of stem cell differentiation, morphology, cell growth and expansion, and clonal efficiency, are driving their adoption. A particular lot of fetal bovine serum is tested extensively for its ability to support in vitro growth and the expansion of undifferentiated stem cell lines. Furthermore, there is a growing trend of adoption of technologically advanced stem cell lines, which poses capabilities, including steam-in-place (SIP) sterilization, filtration for sterility, and many others.

North America is Expected to Dominate the Market Over the Forecast Period

North America is the leading region due to the presence of major market players. The increased funding by government agencies, the presence of leading clinical diagnostics companies, and the rise in focus to develop biopharmaceuticals in North America fueled the regional market.

The United States is expected to be the largest market in the region. As per the report published by Congressional Research Service (2020), more than USD 134.1 billion for research and development (R&D) has been spent by the US government. The federal government in the United States is playing an important role in supporting research and development efforts, leading to scientific breakthroughs and new technologies. The United States is also benefiting from the presence of key market players, such as Merck KGaA, R&D Systems Inc., Rocky Mountain Biologicals, and TCS Biosciences Ltd, which have well-known portfolios of FBS products.

The country is witnessing rapid growth in the biopharmaceutical industry. Thus, research studies are on the rise, and ultimately, the demand for fetal bovine serum is increasing, as it plays a major role in the development or manufacturing of cell lines.

Competitive Landscape

The market for fetal bovine serum is highly competitive, with global and local players. Due to technological advancements, small and mid-sized companies are focusing on market penetration to grab the market share. Some of the companies in the market are Bovogen Biologicals Pty Ltd, General Electric, HiMedia Laboratories, Merck KGaA, PAN-Biotech, R&D Systems Inc, Rocky Mountain Biologicals, TCS Biosciences Ltd, and Thermo Fisher Scientific.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Demand for Fetal Bovine Serum for Research Studies
    • 4.2.2 Expansion of the Biopharmaceutical Industry
    • 4.2.3 Increase in Investments and Funding for Research Interventions
  • 4.3 Market Restraints
    • 4.3.1 High Cost and Chances of Viral Presence in the Product
    • 4.3.2 Decrease in Cattle Herd Population Due to the Increased Demand of Dairy and Meat Products
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product
    • 5.1.1 Charcoal Stripped
    • 5.1.2 Chromatographic
    • 5.1.3 Dialyzed Fetal Bovine Serum
    • 5.1.4 Exosome Depleted
    • 5.1.5 Stem Cell
    • 5.1.6 Other Products
  • 5.2 By Application
    • 5.2.1 Biopharmaceuticals
    • 5.2.2 Cell Culture Media
    • 5.2.3 Human and Animal Vaccine Production
    • 5.2.4 Other Applications
  • 5.3 By End User
    • 5.3.1 Research and Academic Institutes
    • 5.3.2 Biotechnology and Pharmaceutical Industry
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bovogen Biologicals Pty Ltd
    • 6.1.2 GE Healthcare
    • 6.1.3 HiMedia Laboratories
    • 6.1.4 Merck KGaA
    • 6.1.5 PAN-Biotech
    • 6.1.6 R&D Systems Inc.
    • 6.1.7 Rocky Mountain Biologicals
    • 6.1.8 TCS Biosciences Ltd
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 R&D Systems Inc.
    • 6.1.11 BioWest

7 MARKET OPPORTUNITIES AND FUTURE TRENDS